| Literature DB >> 25243153 |
Radek Kroupa1, Jana Jurankova2, Milan Dastych1, Michal Senkyrik1, Tomas Pavlik3, Jitka Prokesova1, Marketa Jecmenova1, Jiri Dolina1, Ales Hep1.
Abstract
BACKGROUND: The aim of this study was to monitor oropharyngeal bacterial colonization in patients indicated for percutaneous endoscopic gastronomy (PEG).Entities:
Mesh:
Year: 2014 PMID: 25243153 PMCID: PMC4163457 DOI: 10.1155/2014/590891
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Summary of patient characteristics according to indication for PEG (n = 274).
| Variable | Neurological disorders ( | Head and neck cancer ( |
| ||
|---|---|---|---|---|---|
|
| % |
| % | ||
| Sex (male) | 116 | 56.3% | 45 | 66.2% | 0.159 |
| Colonizing pathogens | 159 | 77.2% | 31 | 45.6% | <0.001∗ |
| Polymicrobial flora | 75 | 36.4% | 12 | 17.6% | 0.004∗ |
| Pathogens resistant to amoxicillin | 93 | 45.1% | 12 | 17.6% | <0.001∗ |
| Tracheostomy | 67 | 32.5% | 13 | 19.1% | 0.045∗ |
| MRSA infection | 11 | 5.3% | 0 | 0.0% | 0.071 |
| ATB prophylaxis | 206 | 100.0% | 68 | 100.0% | 1.000 |
| Coamoxicillin | 196 | 95.1% | 66 | 97.1% | 0.736 |
| Cefuroxim | 3 | 1.5% | 1 | 1.5% | 1.000 |
| Other | 7 | 3.4% | 1 | 1.5% | 0.684 |
| Serious comorbidities | 32 | 15.5% | 7 | 10.3% | 0.324 |
| PEG site infections | 18 | 8.7% | 12 | 17.6% | 0.070 |
| Other complications | 17 | 8.3% | 12 | 17.6% | 0.040∗ |
| Major complications (bleeding, respiratory) | 5 | 2.4% | 6 | 8.8% | 0.027∗ |
| Minor complications | 12 | 5.8% | 6 | 8.8% | 0.394 |
| 30 days of mortality | 19 | 9.2% | 1 | 1.5% | 0.032∗ |
*Statistically significant at 5% level.
Pathogenic microbial agents colonizing oropharynx or airways in PEG patients and agents isolated from PEG wound in patients with clinically apparent infection.
| Colonizing | Agents | PEG wound infection | |
|---|---|---|---|
| All 274 pts | Neurological/cancer (206/68 pts) | Neurological/cancer (18/12 pts) | |
|
| 63 | 61/2 | 1/0 |
|
| 23 | 16/7 | 2/3 |
|
|
|
|
|
|
| 9 | 9/0 | 2/1 |
|
| 4 | 2/2 | 2/1 |
|
| 33 | 25/8 | 7/0 |
| MSSA (S) | 26 | 20/6 | 4/5 |
|
| 2 | 1/1 | 0/0 |
|
| 14 | 12/2 | 3/1 |
|
| 10 | 6/4 | 0/0 |
|
| 12 | 9/3 | 1/1 |
|
| 6 | 6/0 | 0/1 |
| Streptococ beta hemolytic (S) | 6 | 0/6 | 2/2 |
|
|
|
|
|
(R): amoxicillin resistant (S) amoxicillin sensitive, MRSA: methicillin resistant Staphylococcus aureus, MSSA: methicillin sensitive Staphylococcus aureus.
Characteristic of patients with PEG site infection (N = 30).
| Indication | All | Neurological | Cancer |
|---|---|---|---|
| PEG site infection | 30 (10.9%) | 18 (8.7%) | 12 (17.6%) |
|
|
|
|
|
| Concordance between oropharyngeal and PEG site pathogens | 17 (57%) | 10 (56%) | 7 (58%) |
| ATB prophylaxis | 30 (100%) | 18 (100%) | 12 (100%) |
| Coamoxicillin | 29 (97%) | 17 (94%) | 12 (100%) |
| Cefuroxime | 0 | 0 | 0 |
| Other | 1 (3%) | 1 (6%) | 0 |
| 30 days of mortality | 4 (13%) | 4 (22%) | 0 |
Univariate analysis of possible risk factors with respect to the PEG site infection in all patients and separately for head and neck cancer patients and neurological patients. *Statistically significant at 5% level.
| Variable | All ( | Cancer ( | Neurological ( | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| OR | 95% CI |
| |
| Sex (male) | 1.49 | 0.65–3.39 | 0.330 | 1.03 | 0.27–3.85 | 0.969 | 0.46 | 0.17–1.24 | 0.126 |
| PEG indication (cancer) | 2.24 | 0.95–5.26 | 0.070 | n.a. | n.a. | ||||
| Colonizing pathogens | 1.52 | 0.59–4.07 | 0.408 | 8.33 | 1.66–41.76 | 0.010∗ | 0.75 | 0.25–2.22 | 0.601 |
| Polymicrobial flora | 0.76 | 0.30–1.90 | 0.678 | 3.00 | 0.73–12.34 | 0.128 | 0.47 | 0.15–1.49 | 0.199 |
| Pathogens resistant to amoxicillin | 0.92 | 0.39–2.15 | 1.000 | 1.74 | 0.39–7.71 | 0.466 | 0.97 | 0.37–2.57 | 0.950 |
| MRSA colonization | 3.28 | 0.64–14.80 | 0.107 | n.a. | 4.50 | 1.08–18.76 | 0.039∗ | ||
| Serious comorbidities | 1.24 | 0.39–3.71 | 0.781 | 0.76 | 0.08–6.94 | 0.806 | 1.63 | 0.50–5.32 | 0.416 |
| Tracheostomy | 0.87 | 0.34–2.17 | 0.834 | 1.53 | 0.35–6.70 | 0.570 | 0.78 | 0.27–2.29 | 0.653 |
| Other complications | 0.93 | 0.21–3.54 | 1.000 | 0.37 | 0.04–3.19 | 0.367 | 1.44 | 0.30–6.87 | 0.646 |
n.a.: cannot be evaluated.